This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Non Small Cell Lung Carcinoma

Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC

Sponsored by AstraZeneca

About this trial

Last updated 14 years ago

Study ID

1839IL/0126

Status

Terminated

Type

Interventional

Phase

Phase 3

Placebo

No

Accepting

18-75 Years
18+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 18 years ago

What is this trial about?

The aim of the study if to determine if Iressa can prolong the period of time without any disease worsening (Time to progression) in patients previously treated with combined therapy such as surgery and chemotherapy with or without radiotherapy or chemotherapy and radiotherapy

What are the participation requirements?

Yes

Inclusion Criteria

- Histologically Confirmed Non Small Cell Lung Cancer.

- Locally advanced disease previously treated with combined therapy (chemotherapy and surgery with or without radiotherapy, or chemotherapy and radiotherapy).

- Chemotherapy with regimens containing cisplatin or carboplatin is mandatory

- Response to combined therapy

No

Exclusion Criteria

- No previous treatment with ZD1839 or any other EGFR-targeted therapy

- No progressive disease after combined therapy for locally advanced NSCLC

- No presence of metastatic disease

- No other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ

- Any unresolved chronic toxicity from previous anticancer therapy.

Locations

Location

Status